AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease
AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease - Topline results expected in November 2022 News provided by Share this article Share this article BALTIMORE, April 21, 2021 /PRNewswire/ -- AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD). The clinical trial, known as "HOPE4MCI...
Source: prnewswire.com